RxDoctor Payments Data

Abie Samuel, DO

Rheumatology · St Petersburg, FLNPI 1720287659

Payments from drug & device makers

$19,982in general payments, 2019–2025

Across 1,118 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • Johnson & Johnson$3K
  • Novartis$3K
  • AbbVie$2K
  • UCB, Inc.$1K
  • Pfizer$1K
  • plus $6K from 21 others

What the payments were for

  • Food & beverage$19,77799%
  • Education$1861%
  • Gifts$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,982 in reported general payments places this provider in the 65th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$563,243
Medicare patients
441
Services billed
34,480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab48$405,554
Enbrel SureclickEtanercept41$375,005
RinvoqUpadacitinib23$148,331
Enbrel MiniEtanercept17$146,929
Orencia ClickjectAbatacept18$106,128
ForteoTeriparatide24$104,654
Actemra ActpenTocilizumab18$96,095
Mycophenolate Mofetil57$63,055
OrenciaAbatacept11$62,969
ProliaDenosumab20$34,684
Hydroxychloroquine Sulfate260$11,305
Leflunomide80$5,126
MethotrexateMethotrexate Sodium201$3,633
Alendronate Sodium323$2,215
Prednisone339$2,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,094$148,33123 claims
Lilly USA, LLCForteo$824$104,65424 claims
E.r. Squibb & Sons, L.L.C.Orencia$885$62,96911 claims
AmgenProlia$4,040$34,68420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 453 rheumatology providers in Florida.

Other rheumatology in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →